title: Proof of concept: endogenous antiangiogenic factors predict the occurrence of symptomatic vasospasm post subarachnoid hemorrhage.
abstract: BACKGROUND
  The pathogenesis of vasospasm (VS) post aneurysmal subarachnoid hemorrhage (SAH) is multifactorial and not completely understood. The authors hypothesize that circulating antiangiogenic factors play an important role in brain injury post SAH and that elevated levels predict the occurrence of symptomatic vasospasm.
  
  
  METHODS
  In this study the authors measured the serum and cerebrospinal fluid (CSF) levels of soluble endoglin (sEng) and soluble fms-like tyrosine kinase 1 (sFlt1) in controls and SAH patients within 48 h of the bleed. Patients were prospectively followed and subcategorized into those with (sVS) and without symptomatic vasospasm (no-sVS).
  
  
  RESULTS
  Compared to healthy controls, SAH patients had higher CSF levels of sEng (0.037 vs. 0.251 ng/ml; P = 0.02) and sFlt1 (0.068 vs. 0.679 ng/ml; P = 0.001). In the subgroup analysis, sVS patients had higher CSF levels of sEng and sFlt1 than no-sVS patients (sEng: 0.380 vs. 0.159 ng/ml, P = 0.02; sFlt1: 1.277 vs. 0.343 ng/ml, P = 0.01). The serum levels of sEng and sFlt1 were not statistically different among the different groups.
  
  
  CONCLUSIONS
  Based on these results the authors conclude that elevated CSF levels of sFlt1 and sEng herald the occurrence of symptomatic VS post SAH.
authors: Department of Neurology of the University of Illinois at Chicago, 912 S Wood Street (MC-796), Chicago, IL 60612-7330, USA. testai@uic.edu
authors: Fernando D
authors: FD
authors: Testai
authors: Venkatesh
authors: V
authors: Aiyagari
authors: Maureen
authors: M
authors: Hillmann
authors: Sepideh
authors: S
authors: Amin-Hanjani
authors: Glyn
authors: G
authors: Dawson
authors: Philip
authors: P
authors: Gorelick
references: J Neurosci. 2002 May 15;22(10):3898-909
references: 12019309
references: Stroke. 2003 Feb;34(2):427-33
references: 12574555
references: Acta Neuropathol. 1999 May;97(5):447-55
references: 10334481
references: Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
references: 16633338
references: Nat Clin Pract Neurol. 2007 May;3(5):256-63
references: 17479073
references: J Clin Invest. 2000 Oct;106(7):829-38
references: 11018070
references: Stroke. 2010 Feb;41(2):343-9
references: 20101028
references: Neuroscience. 2009 Mar 17;159(2):744-50
references: 19154781
references: Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2546-52
references: 11116051
references: Stroke. 2011 Apr;42(4):919-23
references: 21350201
references: Prog Growth Factor Res. 1994;5(4):341-51
references: 7540059
references: Am J Pathol. 2000 Mar;156(3):965-76
references: 10702412
references: N Engl J Med. 2006 Sep 7;355(10):992-1005
references: 16957146
references: Neurocrit Care. 2006;5(3):215-21
references: 17290093
references: Am J Physiol. 1996 Dec;271(6 Pt 2):H2735-9
references: 8997338
references: J Cereb Blood Flow Metab. 1993 May;13(3):521-5
references: 8097519
references: Neurosci Lett. 2009 Sep 25;461(3):212-6
references: 19559076
references: Neurology. 1998 May;50(5):1413-8
references: 9595997
references: J Invest Surg. 2010 Jun;23(3):149-55
references: 20590386
references: J Clin Endocrinol Metab. 2007 Jul;92(7):2672-9
references: 17426083
references: Nat Med. 2006 Jun;12(6):642-9
references: 16751767
references: Acta Neurochir Suppl. 2011;110(Pt 1):105-9
references: 21116924
references: J Cereb Blood Flow Metab. 2001 Feb;21(2):157-62
references: 11176281
references: J Cell Biochem. 2007 Dec 15;102(6):1375-88
references: 17975795
references: FASEB J. 2004 Mar;18(3):609-11
references: 14734648
references: Neuroscience. 2004;123(4):897-906
references: 14751283
references: Hypertens Res. 2010 Sep;33(9):892-8
references: 20535121
references: Stroke. 2009 Mar;40(3):994-1025
references: 19164800
references: Mol Pharmacol. 2007 Dec;72(6):1476-83
references: 17848599